URGENT: Kerr & Sheikh, "Waning of first- & second-dose AstraZeneca & Pfizer COVID-19 vaccinations: pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland & Wales"
by Paul Alexander
target trial design for first/second doses of ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) with a composite outcome of COVID-19 hospitalization or death over the period 8 December 2020
Before going further, the researchers stated “Several SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hospitalization and death.”
I will say what many are afraid of saying, there is no study, none, no clinical data to show this. The vaccine trials were designed to test for symptomatic COVID, ONLY. Moreover, when this is stated above and I say false, they do not control for co-morbidities, natural immunity, as well as early treatment.
Now onto the present study:
“A target trial design for first/second doses of ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) with a composite outcome of COVID-19 hospitalization or death over the period 8 December 2020 to 30 June 2021. Exposure groups were matched by age, local authority area and propensity for vaccination.
For Doses 1 and 2 of ChAdOx1 and Dose 1 of BNT162b2, VE/rVE reached zero by approximately Days 60-80 and then went negative. By Day 70, VE/rVE was -25% (95% CI: -80 to 14) and 10% (95% CI: -32 to 39) for Doses 1 and 2 of ChAdOx1, respectively, and 42% (95% CI: 9 to 64) and 53% (95% CI: 26 to 70) for Doses 1 and 2 of BNT162b2, respectively. rVE for Dose 2 of BNT162b2 remained above zero throughout and reached 46% (95% CI: 13 to 67) after 98 days of follow-up.
Found strong evidence of waning in VE/rVE for Doses 1 and 2 of ChAdOx1, as well as Dose 1 of BNT162b2.”